Crystal Induced Arthritis

Slide 1 · Crystal-Induced Arthritis

Gout: molecular mechanisms, joint morphology and clinical correlation

Pathological mechanisms • Morphology • Clinical correlation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish the principal endogenous and exogenous crystals associated with joint injury.

Explain urate homeostasis and the crystal-driven inflammatory cascade in gout.

Recognize the acute, chronic tophaceous and renal morphological manifestations.

Connect the four clinical stages of gout with their pathological substrate.

Slide 3 · Crystal deposition defines a family of arthropathies

Endogenous deposits

Exogenous particulate debris

Monosodium urate (gout)

Calcium pyrophosphate (CPPD)

Basic calcium phosphate

Wear debris from prosthetic biomaterials

Shared outcome: Inflammatory joint injury and cartilage damage

Slide 4 · Crystals generate inflammation and cartilage injury

Crystal deposition

Inflammatory response

Cartilage injury

Joint dysfunction

Both endogenous deposits and exogenous wear debris may elicit destructive joint inflammation.

Slide 5 · Gout is a monosodium urate crystal disease

Transient attacks of acute arthritis begin after monosodium urate deposits in or around joints.

The common substrate is excess uric acid within body fluids and tissues.

Inflammatory attacks may remit, whereas recurrent deposits can produce persistent structural damage.

Slide 6 · Primary and secondary gout: Etiologic distinction

Feature

Primary gout

Secondary gout

Underlying setting

Gout is the dominant manifestation

Another disease or drug contributes to hyperuricemia

Common pathways

Usually reduced urate excretion

Increased synthesis, reduced excretion, or both

Examples

Transport variation; rare salvage enzyme defects

Leukemia cell lysis; chronic kidney disease; drugs

Slide 7 · Hyperuricemia is necessary but not sufficient

> 6.8 mg/dL

Hyperuricemia threshold

Only about 10% of individuals with hyperuricemia develop gout.

Crystallization, time and host susceptibility separate biochemical elevation from clinical disease.

Slide 8 · Serum urate reflects a balance of production and disposal

Purine catabolism

Serum uric acid

Renal excretion

Input

Output

Hyperuricemia may result from greater input, lower clearance, or both.

Slide 9 · Purines come from synthesis and salvage

De novo pathway

Purine nucleotide pool

Purine breakdown

Uric acid

The salvage pathway returns free purine bases to the nucleotide pool; Failed salvage can increase degradation.

Slide 10 · Uric acid is the terminal product of purine breakdown

Purine catabolism generates uric acid.

Increased production may reflect excessive nucleic acid turnover or abnormal purine metabolism.

Purine salvage normally limits loss of reusable bases into degradative pathways.

Slide 11 · Hyperuricemia has two major causal routes

Increased synthesis

Reduced excretion

– Excess purine precursor flux

– Rapid degradation of nucleic acids

– Selected purine enzyme abnormalities

– Renal handling of urate

– Chronic renal disease

– Drug-associated retention of urate

Slide 12 · Renal urate handling shapes steady-state concentration

Glomerular filtration

Strong proximal tubular reabsorption

Small net urinary excretion

Filtration, extensive proximal reclamation, and limited secretion / final elimination.

Slide 13 · Primary gout usually reflects underexcretion

Reduced renal excretion as the usual mechanism in primary gout.

The precise basis remains unknown in many affected people.

A smaller subset has enzyme-mediated increases in uric acid production.

Slide 14 · Transporter-associated susceptibility

Gene named in Robbins

Linked process

URAT1

Renal urate transport and homeostasis

GLUT9

Urate transport and homeostasis

KCNQ1

Ion transport/homeostasis association in genetic studies

Slide 15 · Partial HGPRT deficiency impairs purine salvage

Partial HGPRT deficiency

Reduced purine salvage

More purine degradation

Excess uric acid

HGPRT = hypoxanthine–guanine phosphoribosyltransferase; A rare cause of primary gout.

Slide 16 · Complete HGPRT deficiency has a broader phenotype

Complete loss of HGPRT causes prominent hyperuricemia.

Severe neurological manifestations dominate the clinical picture in Lesch–Nyhan syndrome.

Robbins therefore places this presentation among secondary causes of gout.

Slide 17 · Cell lysis can produce secondary hyperuricemia

Rapid cell lysis

Nucleic acid breakdown

Purine catabolism

Urate production ↑

Example: Chemotherapy-associated rapid cell lysis in leukemia.

Slide 18 · Chronic kidney disease promotes urate retention

Chronic renal disease

Impaired urate excretion

Hyperuricemia

Crystal risk

Mechanistic linkage is reduced excretion, not obligatory urate overproduction.

Slide 19 · Some drugs reduce urate excretion

Thiazides are specifically listed by Robbins as medicines that reduce excretion.

Drug exposure is a modifiable component of the clinical history.

A medication-associated rise in urate remains distinct from proof of crystal arthritis.

Slide 20 · Host and exposure factors modify risk

Susceptibility

Urate / ion transporter variants

Duration

Long-standing hyperuricemia

Lifestyle

Alcohol consumption; Obesity

Medication

Thiazides decrease excretion

Slide 21 · Hyperuricemia may precede gout by decades

20–30 years

Typical duration of hyperuricemia before clinical gout

Age and duration of exposure both influence disease expression.

Hyperuricemia alone cannot predict which person will develop symptomatic arthritis.

Slide 22 · Gout begins when urate precipitates inside a joint

Schematic: Not a histological or clinical image

Urate crystals

Monosodium urate precipitates in the joint.

Synovial lining

Resident inflammatory cells respond to crystals.

Slide 23 · Synovial phagocytes encounter precipitated crystals

Joint urate crystals

Macrophage / neutrophil uptake

Intracellular crystal sensing

Mediator release

Resident synovial macrophages participate early in the inflammatory response.

Slide 24 · The inflammasome initiates IL-1 maturation

Phagocytosed crystal

Inflammasome sensing

Caspase-1 activation

Active IL-1

This source-defined axis is a key molecular explanation for the acute flare.

Slide 25 · IL-1 recruits inflammatory leukocytes

Active IL-1

Leukocyte recruitment

More phagocytosis

Amplified synovitis

Neutrophils and macrophages accumulate in the joint.

Slide 26 · Phagolysosomal disruption worsens inflammation

Crystal ingestion

Phagolysosomal injury

Proteases / mediators

Tissue injury

Urate crystal uptake may rupture phagolysosomes.

Slide 27 · Neutrophils perpetuate the acute flare

Crystal phagocytosis

Neutrophil injury

Release of enzymes + crystals

Recruited leukocytes

Slide 28 · Complement contributes to leukocyte recruitment

The alternative complement pathway may become activated during an acute gouty attack.

This provides additional chemotactic signals to recruit inflammatory cells.

Complement amplifies rather than replaces the inflammasome–IL-1 pathway.

Slide 29 · A mediator cascade causes abrupt painful synovitis

Cytokines + proteases

Free radicals + eicosanoids

Synovial tissue injury

Acute joint inflammation

Multiple mediators explain the intensity of crystal-induced acute arthritis.

Slide 30 · Acute inflammation can resolve without curing urate excess

The inflammatory episode often remits within days to weeks.

Remission occurs as the crystallization episode subsides and crystals are solubilized.

The underlying tendency toward excess urate may persist after symptoms disappear.

Slide 31 · Gout produces four distinctive pathological patterns

Acute arthritis

Neutrophil-rich synovitis

Chronic tophaceous arthritis

Persistent deposits and erosion

Extraarticular tophi

Deposits in soft tissues

Urate nephropathy

Renal stones/interstitial deposits

Slide 32 · Acute gout: Neutrophil-rich synovial inflammation

Schematic: Not a histological or clinical image

Neutrophil-rich synovitis

Inflammatory cells enter fluid and synovium.

Edema and congestion

Acute changes cause severe pain and swelling.

Slide 33 · Needle-shaped monosodium urate crystals

Schematic of needle-shaped MSU crystals

Needle-shaped

Often intracellular in neutrophils

Negative birefringence

Slide 34 · Compensated polarization identifies negative birefringence

Compensated polarization — schematic

Parallel to polarizer → yellow

Perpendicular → blue

MSU crystals are negatively birefringent.

Slide 35 · The acute synovium is edematous and congested

Neutrophils densely permeate the synovium and joint fluid.

Edema and vascular congestion accompany the acute inflammatory response.

Lymphocytes, plasma cells and macrophages may also be present.

Slide 36 · Intracellular crystals link morphology to pathogenesis

In aspirated fluid

Pathogenetic meaning

– Needle-shaped crystals

– Frequently contained in neutrophils

– Best recognized using polarized light

– Phagocytosis has occurred

– Leukocyte activation drives mediator release

– Crystals identify the injury trigger

Slide 37 · Repeated flares convert transient injury to chronic disease

Deposition

Initial crystal load

Acute flares

Recruited neutrophils

Repetition

Synovial remodeling

Chronic damage

Cartilage and bone erosion

Slide 38 · Chronic gout produces chalky articular deposits

Schematic: Not a histological or clinical image

Chalky tophaceous deposits

Repeated episodes enlarge crystal burden.

Synovial remodeling

Hyperplasia, fibrosis and chronic infiltration.

Slide 39 · Persistently inflamed synovium becomes thick and fibrotic

Synovial hyperplasia develops with repeated urate precipitation.

Fibrosis and inflammatory-cell infiltration thicken the membrane.

Chalky deposits may encrust articular cartilage and synovium.

Slide 40 · Pannus damages cartilage and adjacent bone

Schematic: Not a histological or clinical image

Pannus and tophi

Persistent tissue reaction damages cartilage.

Subchondral bone erosion

Juxtaarticular injury produces disability.

Slide 41 · Severe chronic injury can result in ankylosis

Chronic synovitis

Cartilage destruction

Juxtaarticular erosion

Fibrous / bony ankylosis

End-stage change compromises joint function.

Slide 42 · Tophi are the pathological hallmark of gout

Original schematic — not a histology specimen

Central urate aggregates

Surrounding giant cells

Chronic inflammatory tissue

Slide 43 · Tophi evoke a foreign-body giant-cell response

Large crystal aggregates form a focus for intense inflammatory reaction.

Foreign-body multinucleated giant cells surround deposits.

Chronic inflammatory cells and reactive tissue accompany the crystals.

Slide 44 · Tophi involve joint and periarticular structures

Articular cartilage

Within joints

Tendons / ligaments

Periarticular

Bursae

Joint-adjacent soft tissue

Earlobes / fingertips

Extraarticular

Kidneys

Less frequent

Slide 45 · Extraarticular tophi extend beyond the synovium

Tophi can form in earlobes and fingertips.

Tendons, ligaments and bursae are additional recognized sites.

Renal tophi are less common and contribute to extraarticular disease.

Slide 46 · Urate nephropathy reflects crystal-associated renal injury

Tubular / interstitial crystal deposits

Schematic: Deposits may involve medullary interstitium or tubules

Uric acid nephrolithiasis

Potential obstruction

Pyelonephritis complication

Slide 47 · Uric acid stones may produce obstructive complications

Urate-related renal disease

Uric acid nephrolithiasis

Urinary obstruction

Pyelonephritis risk

Pyelonephritis when obstruction develops.

Slide 48 · Gout passes through four recognizable clinical stages

Asymptomatic

Hyperuricemia

Acute

Painful arthritis

Intercritical

Symptom-free interval

Chronic

Tophaceous gout

Slide 49 · Asymptomatic hyperuricemia is the first clinical stage

May develop around puberty in males.

Often begins after menopause in females.

Biochemical elevation need not coincide with current joint inflammation.

Slide 50 · Acute gout presents as a sudden inflammatory attack

Sudden onset of excruciating joint pain.

Local hyperemia, warmth and sometimes mild fever.

Most initial presentations involve a single joint.

Slide 51 · First metatarsophalangeal arthritis is characteristic

~50%

First attacks affecting the first metatarsophalangeal joint

The classical presentation is sudden, severe first-MTP monoarthritis.

Other joints can be involved; Site alone does not establish the cause.

Slide 52 · The intercritical interval is symptom-free

An interval without symptoms follows an acute flare.

An individual may never experience another attack, although recurrence is common.

Residual biochemical risk does not disappear simply because pain resolves.

Slide 53 · Untreated attacks may become more frequent and widespread

Initial

Monoarthritis

Recurrence

Repeated flares

Progression

Shorter intervals

Later

Polyarticular disease

Slide 54 · Chronic tophaceous gout erodes the joint

Chronic tophaceous disease about 10 years after the first attack.

Juxtaarticular erosions and loss of joint space occur.

Joint function may be severely compromised.

Slide 55 · The clinical stage mirrors a distinct tissue process

Clinical stage

Dominant substrate

Key implication

Asymptomatic

Excess urate without flare

Hyperuricemia ≠ symptomatic gout

Acute arthritis

Crystal-driven neutrophilic synovitis

Severe pain, warmth, erythema

Intercritical

Flare resolved

Recurrence remains possible

Chronic tophaceous

Tophi, pannus, erosions

Permanent joint damage

Slide 56 · Finding crystals provides morphological specificity

Supportive observations

Interpretation cautions

– Acute inflammatory synovial fluid

– Intracellular slender needles

– Negative birefringence

– Hyperuricemia alone is not a tissue diagnosis

– A pain-free interval is not cure

– Clinical distribution is suggestive, not uniquely diagnostic

Slide 57 · Gout and CPPD have contrasting crystal morphologies

Feature

Gout: MSU

CPPD (separate topic)

Crystal shape

Slender needles

Rhomboid crystals

Compensated polarization

Negative birefringence

Positive birefringence

Color parallel to polarizer

Yellow

Blue

Typical deposit emphasis

Urate in joint/periarticular tissues

CPP crystals form in cartilage

Slide 58 · Crystal-induced arthritis is not one uniform disease

Endogenous deposits

Exogenous particulate debris

Urate → gout

Calcium pyrophosphate → CPPD

Basic calcium phosphate

Prosthetic material → wear-associated inflammation

Shared outcome: Inflammatory joint injury and cartilage damage

Slide 59 · Acute and chronic gout differ morphologically

Pathological feature

Acute attack

Chronic tophaceous disease

Inflammatory cells

Dense neutrophils

Chronic inflammatory infiltrates, giant cells

Crystal disposition

Needles in fluid / synovium

Tophi and surface encrustations

Tissue injury

Edema and acute synovitis

Fibrosis, pannus, erosions

Clinical implication

Severe episodic symptoms

Structural loss of function

Slide 60 · Nonpharmacologic care addresses modifiable exposures

Weight reduction in obese individuals.

Lower dietary purine intake, alcohol and sugar-sweetened beverages.

Regular exercise forms part of the source-described management approach.

Slide 61 · Urate-lowering therapies act on different processes

Drug class

Representative named in Robbins

Pathway targeted

Uricosuric agent

Probenecid

Increases urate elimination

Xanthine oxidase inhibitor

Allopurinol

Decreases urate synthesis

Urate oxidase (uricase)

Uricase preparations

Promotes urate degradation

Slide 62 · Acute inflammatory symptoms require separate control

NSAIDs and colchicine are listed as anti-inflammatory treatments for gout.

Acute flare control addresses inflammation, not necessarily the urate excess.

Chronic crystal burden and recurrent inflammation are conceptually separate therapeutic targets.

Slide 63 · Therapy can target urate burden or synovitis

Upstream: Urate burden

Downstream: Acute inflammation

– Reduce synthesis

– Increase clearance

– Enzymatic urate removal

– Interrupt mediator effects

– Limit inflammatory-cell responses

– Relieve a symptomatic attack

Slide 64 · Case: A sudden red and painful first-MTP joint

An adult develops overnight severe pain, warmth and redness of the first metatarsophalangeal joint. Aspirated fluid contains neutrophils with slender needles.

Which crystal property best supports gout?

Needle-shaped monosodium urate crystals with negative birefringence on compensated polarization.

Slide 65 · Case: Chronic nodules and progressive joint damage

A patient with a decade of recurring acute attacks develops periarticular nodules and progressively restricted joint movement.

What two tissue processes explain the evolving disability?

Tophus formation with chronic inflammatory pannus, followed by cartilage destruction and juxtaarticular bone erosion.

Slide 66 · Integrated mechanism: From urate excess to joint destruction

Urate excess

Crystal precipitation

IL-1 / leukocyte response

Recurrent injury

Tophi + erosion

Repetition of acute crystal-driven inflammation connects biochemical risk with permanent structural disease.

Slide 67 · Core distinctions to retain

Hyperuricemia is required in the Robbins mechanism but is not sufficient for gout.

MSU needles, intracellular crystals and negative birefringence characterize an acute attack.

Tophi, pannus and erosions define the chronic destructive phenotype.

CPPD and other crystal arthropathies are related but biologically distinct.

Slide 68 · Primary reference and image policy

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026), Ch. 26, pp. 1094–1096.

Gout excerpt and Fig. 26.38–26.39 captions supplied in the project source text.

CPPD crystal comparison drawn from the adjacent textbook section, pp. 1096–1097.

All figures in this lecture are editable original schematics, not observed photomicrographs.